Aug 18, 2025 • Benzinga
BULLISH
Why Is Carlsmed Stock Gaining Monday? - Carlsmed ( NASDAQ:CARL )
CMS grants NTAP reimbursement of up to $21,125 for Carlsmed's spine implants. BofA forecasts 66% revenue growth in 2025, Buy rating with $16 target. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here → Carlsmed Inc.
Aug 13, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Aug 13, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Aug 11, 2025 • Zacks Commentary
BULLISH
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Globus Medical ( GMED ) Q2 Revenue Up 18%
Globus Medical ( NYSE:GMED ) , a spinal and musculoskeletal medical device company, reported its Q2 2025 earnings on August 7, 2025. The main highlight was a jump in headline net income ( GAAP ) in Q2 2025, driven by unique, non-operational items such as a major acquisition gain and a one-time ...
Aug 07, 2025 • Zacks Commentary
NEUTRAL
Globus Medical ( GMED ) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +13.16% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?